Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000515633 | SCV002486363 | likely benign | not provided | 2024-12-04 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000515633 | SCV005256281 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Ce |
RCV000515633 | SCV005909962 | likely benign | not provided | 2025-03-01 | criteria provided, single submitter | clinical testing | KANK4: BS2 |
OMIM | RCV000515633 | SCV000611734 | uncertain significance | not provided | 2017-11-27 | no assertion criteria provided | literature only | |
Yale Center for Mendelian Genomics, |
RCV001849394 | SCV002106691 | likely pathogenic | Nephrotic syndrome | 2017-11-10 | no assertion criteria provided | literature only | |
Prevention |
RCV003962424 | SCV004791206 | likely benign | KANK4-related disorder | 2022-04-01 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |